Podcast with Dr. Delvys Rodriguez-Abreu about pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: 3-year follow-up of Keynote-598 Back to previous page